Cassava Sciences | PTIE - Operating Expenses


Cassava Sciences reported $11.86M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
Amgen USD 5.13B 1.39B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Cassava Sciences USD 11.86M 2.23M Sep/2025
Eisai JPY 183.69B 1.78B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Geron USD 61.11M 376K Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Merck USD 10.72B 1.28B Sep/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025